Variable | PML (n = 4) | PCNSL (n = 7) | GBM (n = 11) | P |
---|---|---|---|---|
Age (years) ± SD | 52.3 ± 6.1 | 74.4 ± 5.8 | 65.0 ± 15.2 | N.S |
Male:female | 2:2 | 3:4 | 6:5 | N.S |
Mean MTRasym ± SD (lesion) | 0.005 ± 0.005 | 0.025 ± 0.005 | 0.025 ± 0.009 | 0.012 |
Mean MTRasym ± SD (normal-appearing tissue) | 0.003 ± 0.002 | 0.003 ± 0.002 | 0.004 ± 0.002 | 0.389 |
T1 low intensity | 2 (50%) | 3 (42.9%) | 6 (54.5%) | 0.890 |
T2 hyperintensity | 4 (100%) | 6 (85.7%) | 10 (90.9%) | 0.730 |
Tumor location (above the tentorium) | 3 (75%) | 6 (85.7%) | 11 (100%) | 0.279 |
Multiple lesions | 3 (75%) | 4 (57.1%) | 7 (63.6%) | 0.839 |
Contralateral lesions | 3 (75%) | 3 (42.9%) | 4 (36.4%) | 0.408 |
Mass effect | 0 (0%) | 7 (100%) | 11 (100%) | < 0.001 |
Enhancement | 0 (0%) | 7 (100%) | 11 (100%) | < 0.001 |
Poor enhancement area | 0 (0%) | 0 (0%) | 10 (90.9%) | < 0.001 |
Edema around the lesion | 0 (0%) | 7 (100%) | 10 (90.9%) | < 0.001 |
3D ASL hyperintensity | 0 (0%) | 3 (42.9%) | 9 (81.8%) | 0.014 |